In recent years fentanyl overdoses have vastly increased across the United States. The current opioid crisis is driven by fentanyl and its analogues and according to the National Center for Health Statistics, the powerful substance is estimated to have accounted for 64,070 deaths in the US last year, a rise of 21% from 2015.
Other opioids are being adulterated with fentanyl derivatives, specifically heroin. Fentanyl is sometimes sold as methylenedioxymethamphetamine (MDMA), or ecstasy, increasing the number of poly drug users as many users might be unaware that their expected substance of choice has been substituted or adulterated with high doses of fentanyl. In turn, the difficulty of detecting which drug is in the patient’s system is greater.
Designed to work across multiple matrices including urine, oral fluid and whole blood, our latest biochip array technology panel NPS II detects fentanyl and its analogues from one single sample giving a full portfolio drug screen. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result.
Additionally, Randox Toxicology provide highly sensitive and precise ELISA kits for the rapid detection of fentanyl and carfentanil/remifentanil as well as an exclusive range of new psychoactive substance ELISA tests.
Our representative Pankaj Sinha will be presenting on our latest fentanyl innovations at the SAT conference on Friday 3rd November at 9:00am:
'Application of biochip array technology to maximise the screening of illicit fentanyl compounds and derivatives from one undivided urine sample.'
For more information about our fentanyl and analogous screening email us at email@example.com